Drug Interactions Database

6278 interactions from BNF 85 - Check your medicines

Source: BNF 85
Severity: All 6278 Severe 944 Moderate 1418 Unknown 3916
opicapone moclobemide

increases risk of elevatedbloodpressure

Severe Theoretical
opicapone moclobemide

increases risk of elevatedbloodb pressure

Severe Theoretical
opicapone montelukast

increases exposure

Severe Study
opicapone pioglitazone

increases exposure

Severe Study
oralaceinhibitors(magnesiumcarbonate- containingforms oraltetracyclines

decreases absorption

Severe Study
oralantacids estramustine

decreases absorption

Severe Study
oralantacids oralalkylatingagents

decreases absorption

Severe Study
oralantacids oralestramustine

decreases absorption

Severe Study
oralantacids orallapatinib

decreases absorption

Severe Theoretical
oralantacids theactivemetaboliteoforalbaloxavirmarboxil

decreases concentration

Severe Theoretical
oralcalciumsalts theactivemetaboliteoforalbaloxavirmarboxil

decreases concentration

Severe Theoretical
oraliron theactivemetaboliteoforalbaloxavirmarboxil

decreases concentration

Severe Theoretical
oralmagnesium theactivemetaboliteoforalbaloxavirmarboxil

decreases concentration

Severe Theoretical
oralquinapril oraltetracyclines

decreases absorption

Severe Study
oralselenium theactivemetaboliteoforalbaloxavirmarboxil

decreases concentration

Severe Theoretical
oralzinc oralclodronate

decreases absorption

Severe Study
oralzinc theactivemetaboliteoforalbaloxavirmarboxil

decreases concentration

Severe Theoretical
osilodrostat tizanidine

increases exposure

Severe Study
oxcarbazepine bictegravir

decreases exposure

Severe Theoretical
oxcarbazepine velpatasvir

decreases exposure

Severe Theoretical
oxcarbazepine voxilaprevir

decreases concentration

Severe Theoretical
oxybutynin antiepileptics

increases risk of overheatinganddehydration

Severe Theoretical
ozanimod linezolid

increases risk of ahypertensivecrisis

Severe Theoretical
ozanimod moclobemide

increases risk of ahypertensivecrisis

Severe Theoretical
panobinostat pimozide

increases exposure

Severe Theoretical
phenobarbital cholicacid

decreases effects

Severe Study
phenobarbital ketoconazole

decreases concentration

Severe Study
phenobarbital posaconazole

decreases concentration

Severe Study
phenothiazines dopaminereceptoragonists

decreases effects

Severe Theoretical
phenytoin dabigatran

decreases exposure

Severe Theoretical
phenytoin thrombininhibitors

decreases exposure

Severe Theoretical
pibrentasvirwithglecaprevir dabigatran

increases exposure

Severe Study
pibrentasvirwithglecaprevir thrombininhibitors

increases exposure

Severe Study
pimecrolimus mifamurtide

decreases efficacy

Severe Theoretical
pimozide dopaminereceptoragonists

decreases effects

Severe Theoretical
pitolisant combinedhormonalcontraceptives

decreases efficacy

Severe Theoretical
pitolisant docetaxel

decreases exposure

Severe Theoretical
pitolisant taxanes

decreases exposure

Severe Theoretical
pitolisant temsirolimus

decreases exposure

Severe Theoretical
posaconazole antiarrhythmics

increases exposure

Severe Theoretical
posaconazole antipsychotics,secondgeneration

increases exposure

Severe Study
posaconazole atorvastatin

increases exposure

Severe Anecdotal
posaconazole disopyramide

increases exposure

Severe Theoretical
posaconazole dronedarone

increases exposure

Severe Theoretical
posaconazole lurasidone

increases exposure

Severe Study
posaconazole statins

increases exposure

Severe Anecdotal
potassiumaminobenzoate sulfonamides

affects efficacy

Severe Theoretical
potassiumcitrate methenamine

decreases efficacy

Severe Theoretical
pralsetinib ciclosporin

affects exposure

Severe Theoretical
pralsetinib warfarin

affects exposure

Severe Theoretical
Prev 1 ... 11 12 13 14 15 ... 126 Next
6278 interactions
Important: This database uses data from the British National Formulary (BNF 85). It is for informational purposes only and is not a substitute for professional medical advice.